AdooQ BioScience is a supplier of biochemicals located in Irvine, CA since 2006. In the past five years, we have been a renowned name engaged in manufacturing and supplying small molecule inhibitors including kinase inhibitors on kinds of signal pathway, such as PI3K, AKT, HDAC, MARP etc.
Company WebsiteAstemizole is a potent antihistamine (H1-receptor antagonist, IC50 = 4 nM) that displays selectivity over dopamine, 5-HT, and muscarinic acetylcholine receptors. This compound has shown potent hERG K+ channel blocking activity (IC50 = 0.9 nM), antimalarial activity in multidrug resistant strains in vitro (IC50 = 227 – 734 nM), and has been used as a […]
More Information Supplier PageAstragalin is a chemical compound. It can be isolated from Phytolacca americana or in the methanolic extract of fronds of the fern Phegopteris connectilis.
More Information Supplier PageAstragalin is a chemical compound. It can be isolated from Phytolacca americana or in the methanolic extract of fronds of the fern Phegopteris connectilis.
More Information Supplier PageAstragalin is a chemical compound. It can be isolated from Phytolacca americana or in the methanolic extract of fronds of the fern Phegopteris connectilis.
More Information Supplier PageAstragaloside A is a novel regulator of HIF-1?? and angiogenesis through the PI3K/Akt pathway in HUVECs that are exposed to hypoxia.
More Information Supplier PageAstragaloside A is a novel regulator of HIF-1?? and angiogenesis through the PI3K/Akt pathway in HUVECs that are exposed to hypoxia.
More Information Supplier PageAstragaloside A is a novel regulator of HIF-1?? and angiogenesis through the PI3K/Akt pathway in HUVECs that are exposed to hypoxia.
More Information Supplier PageAstragaloside A is a novel regulator of HIF-1?? and angiogenesis through the PI3K/Akt pathway in HUVECs that are exposed to hypoxia.
More Information Supplier PageAstragaloside A is a novel regulator of HIF-1?? and angiogenesis through the PI3K/Akt pathway in HUVECs that are exposed to hypoxia.
More Information Supplier PageAstragaloside II induces osteogenic activities of osteoblasts through the bone morphogenetic protein-2/MAPK and Smad1/5/8 pathways.
More Information Supplier PageAstragaloside II induces osteogenic activities of osteoblasts through the bone morphogenetic protein-2/MAPK and Smad1/5/8 pathways.
More Information Supplier PageAstragaloside II induces osteogenic activities of osteoblasts through the bone morphogenetic protein-2/MAPK and Smad1/5/8 pathways.
More Information Supplier PageAstragaloside I, II, III, and IV concentration-dependently increased the CD45-mediated of pNPP/OMFP hydrolysis with the EC50 values ranged from 3.33 to 10.42 ug/mL.
More Information Supplier PageAstragaloside I, II, III, and IV concentration-dependently increased the CD45-mediated of pNPP/OMFP hydrolysis with the EC50 values ranged from 3.33 to 10.42 ug/mL.
More Information Supplier PageAstragaloside I, II, III, and IV concentration-dependently increased the CD45-mediated of pNPP/OMFP hydrolysis with the EC50 values ranged from 3.33 to 10.42 ug/mL.
More Information Supplier PageAT-56 is am orally active inhibitor of lipocalin-type prostaglandin D synthase (L-PGDS) (Ki = 75 ??M, IC50 = 95 ??M).
More Information Supplier PageAT-56 is am orally active inhibitor of lipocalin-type prostaglandin D synthase (L-PGDS) (Ki = 75 ??M, IC50 = 95 ??M).
More Information Supplier PageAT-56 is am orally active inhibitor of lipocalin-type prostaglandin D synthase (L-PGDS) (Ki = 75 ??M, IC50 = 95 ??M).
More Information Supplier PageAT-56 is am orally active inhibitor of lipocalin-type prostaglandin D synthase (L-PGDS) (Ki = 75 ??M, IC50 = 95 ??M).
More Information Supplier PageAT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.32??M, 0.48??M and 0.18??M.
More Information Supplier PageAT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.32??M, 0.48??M and 0.18??M.
More Information Supplier PageAT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.32??M, 0.48??M and 0.18??M.
More Information Supplier PageAT-406 is an orally bioavailable inhibitor of IAP family of proteins with potential apoptotic inducing and antineoplastic activity. AT-406 selectively inhibits the biological activity of IAP proteins, including X chromosome-linked IAP (XIAP), the cellular IAPs 1 (c-IAP1) and 2 (c-IAP2) and melanoma inhibitor of apoptosis protein (ML-IAP).
More Information Supplier PageAT-406 is an orally bioavailable inhibitor of IAP family of proteins with potential apoptotic inducing and antineoplastic activity. AT-406 selectively inhibits the biological activity of IAP proteins, including X chromosome-linked IAP (XIAP), the cellular IAPs 1 (c-IAP1) and 2 (c-IAP2) and melanoma inhibitor of apoptosis protein (ML-IAP).
More Information Supplier PageAT-406 is an orally bioavailable inhibitor of IAP family of proteins with potential apoptotic inducing and antineoplastic activity. AT-406 selectively inhibits the biological activity of IAP proteins, including X chromosome-linked IAP (XIAP), the cellular IAPs 1 (c-IAP1) and 2 (c-IAP2) and melanoma inhibitor of apoptosis protein (ML-IAP).
More Information Supplier PageAT-406 is an orally bioavailable inhibitor of IAP family of proteins with potential apoptotic inducing and antineoplastic activity. AT-406 selectively inhibits the biological activity of IAP proteins, including X chromosome-linked IAP (XIAP), the cellular IAPs 1 (c-IAP1) and 2 (c-IAP2) and melanoma inhibitor of apoptosis protein (ML-IAP).
More Information Supplier PageAT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.32 ??M, 0.48 ??M and 0.18 ??M; does not inhibit BIR3 domain and BID
More Information Supplier PageAT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.32 ??M, 0.48 ??M and 0.18 ??M; does not inhibit BIR3 domain and BID
More Information Supplier PageAT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.32 ??M, 0.48 ??M and 0.18 ??M; does not inhibit BIR3 domain and BID
More Information Supplier PageAT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.32 ??M, 0.48 ??M and 0.18 ??M; does not inhibit BIR3 domain and BID
More Information Supplier PageAT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.32 ??M, 0.48 ??M and 0.18 ??M; does not inhibit BIR3 domain and BID
More Information Supplier PageAT13148 is a novel oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity, which shows a distinct mechanism of action from other AKT inhibitors.
More Information Supplier PageAT13148 is a novel oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity, which shows a distinct mechanism of action from other AKT inhibitors.
More Information Supplier PageAT13148 is a novel oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity, which shows a distinct mechanism of action from other AKT inhibitors.
More Information Supplier PageAT13148 is a novel oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity, which shows a distinct mechanism of action from other AKT inhibitors.
More Information Supplier PageAT13387 is a targeted inhibitor of Hsp90,inhibiting its chaperone function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival.
More Information Supplier PageAT13387 is a targeted inhibitor of Hsp90,inhibiting its chaperone function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival.
More Information Supplier PageAT13387 is a targeted inhibitor of Hsp90,inhibiting its chaperone function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival.
More Information Supplier PageAT13387 is a targeted inhibitor of Hsp90,inhibiting its chaperone function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival.
More Information Supplier PageAT13387 is a targeted inhibitor of Hsp90,inhibiting its chaperone function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival.
More Information Supplier Page
